In vitro, OPS-2071 suppressed TNF-α production induced by LPS stimulation and T cell responses in a dose-dependent manner. At high concentrations, these effects were comparable to those of existing immunosuppressive agents, such as prednisolone, in both mouse and human cells. OPS-2071 also showed antibacterial activity against IBD-related ...

assess the efficacy and safety of 3 doses of OPS-2071 (150, 300, or 600 mg BID) in subjects with Crohn’s disease showing symptoms of active inflammation despite ongoing treatment. OPS-2071 will be added to ongoing treatment for Crohn’s disease, with some restrictions.

OPS-2071 is a novel quinolone antibiotic with low oral absorption and potent antibacterial activity against Clostridioides difficile. This study was conducted to confirm the antimicrobial activity of OPS-2071 against major enteropathogenic bacteria and …

2021年8月31日 · 因此，在 IBD 模型中，我们评估了 OPS-2071（一种用于肠道感染的低吸收喹诺酮类抗菌剂）的治疗效果，并研究了其作用机制。 方法使用幼稚CD4 + T细胞转移IBD模型小鼠评估OPS-2071和比较疗法的治疗效果。 使用小鼠脾细胞和人外周血单核细胞评估 LPS 诱导的 TNF-α 产生的体外抑制和对使用抗 CD3/CD28 抗体负载珠刺激的 T 细胞反应的抑制作用。 此外，还测试了针对与 IBD 发病机制有关的细菌的体外活性。 结果与载体组相比，OPS-2071 剂量依赖 …

2022年9月6日 · 9月1日，大冢制药新药项目OPS-2071片IND申请获得CDE受理。资料显示，OPS-2071属于氟喹诺酮类化合物家族，目前正在开发用于克罗恩病（Crohn's disease）的治疗，在境外已完成Ⅱ期临床试验。之前曾研究用于肠道感染，不过目前该适应症已策略性终止。

ops-2071是由大冢制药株式会社研发的一种小分子药物，是一种lps抑制剂。 目前该药物最高研发阶段为临床二期，用于治疗肠易激综合征。 OPS-2071-靶点: LPS_适应症: 肠易激综合征-临床_专利_批准

2021年8月31日 · In vitro, OPS-2071 suppressed TNF-α production induced by LPS stimulation and T cell responses in a dose-dependent manner. At high concentrations, these effects were comparable to those of existing immunosuppressive agents, such as prednisolone, in both mouse and human cells.

OPS-2071, a novel agent synthesized by Otsuka Pharmaceutical Co., Ltd, has broad and strong antibacterial activity with low systemic absorption. In this study, we have evaluated the therapeutic effect of OPS-2071 on murine T cell-mediated colitis and in vitro activity on T cell activation, cytokine production and antibacterial activity.

OPS-2071 demonstrated significant therapeutic effect on colonic inflammation, suppressed TNF-α production in vitro and showed in vitro activity against bacteria related to CD. From these in vitro results, it can be concluded that OPS-2071 has anti-inflammatory activity, independent of its antibacterial activity.

2021年1月25日 · OPS-2071 exhibited potent antibacterial activity against 54 clinically isolated C. difficile strains with a minimum inhibitory concentration of 0.125 μg/mL (MIC50) and 0.5 μg/mL (MIC90), making...